Key Takeaways
- cobas Respiratory flex test with TAGS technology allows the detection of up to 15 targets in a single PCR test.
- The cobas Respiratory flex test can detect 12 common respiratory viruses, including SARS-CoV-2.
- Customizable testing improves diagnostic accuracy and efficiency.
- Digital reflex capability reduces the need for multiple follow-up tests.
- The test simplifies laboratory logistics, optimizing resource use.
In a significant leap for molecular diagnostics, Roche has unveiled the cobas® Respiratory flex test, powered by its innovative TAGS (Temperature-Activated Generation of Signal) technology. This new test dramatically enhances the capacity of high throughput molecular diagnostic analyzers, capable of identifying up to 15 pathogens in a single patient sample. The cobas Respiratory flex test promises more efficient and rapid diagnosis of respiratory infections, addressing the critical need for timely and accurate detection in clinical settings.
Roche’s TAGS technology represents a groundbreaking advancement in multiplex polymerase chain reaction (PCR) testing. Unlike traditional PCR tests, which typically detect four results per test, TAGS extends this capability to fifteen, utilizing a combination of color, temperature, and data processing. This technology is incorporated into Roche’s high throughput analyzers—cobas® 5800, 6800, and 8800—allowing comprehensive syndromic panel testing, particularly useful in diagnosing respiratory illnesses with overlapping symptoms.
cobas Respiratory Flex Test Enhances Rapid Diagnosis and Treatment of Respiratory Viruses
“Accurate and rapid diagnosis is crucial in managing respiratory outbreaks and combating antibiotic resistance,” stated Matt Sause, CEO of Roche Diagnostics. “The cobas Respiratory flex test, leveraging TAGS technology, allows clinicians to pinpoint specific respiratory viruses swiftly, facilitating timely and appropriate patient care.”
The cobas Respiratory flex test can detect up to 12 common respiratory viruses, including influenza A and B, Respiratory Syncytial Virus (RSV), and SARS-CoV-2, from a single patient sample. Clinicians can customize the test by selecting specific pathogens based on factors such as seasonality and patient demographics. This targeted approach eliminates the delays associated with multiple follow-up tests, thereby expediting diagnosis and treatment. The test’s digital reflex capability further enhances efficiency by enabling the immediate generation of additional results without the need for new samples.
cobas Respiratory Flex Test Revolutionizes Laboratory Efficiency and Diagnostics with TAGS Technology
By delivering comprehensive results in one PCR test, the cobas Respiratory flex test simplifies laboratory logistics, optimizing resource use and reducing lab workload. Currently available in CE-mark-accepting countries, Roche is also pursuing FDA 510(k) clearance in the U.S., with submission planned for Q4. The cobas Respiratory flex test, underpinned by Roche’s pioneering TAGS technology, marks a substantial enhancement in the realm of molecular diagnostics. Its ability to detect multiple pathogens from a single sample significantly improves diagnostic speed and accuracy, crucial in managing respiratory illnesses and curbing antibiotic resistance.
With its customizable and efficient testing capabilities, the cobas Respiratory flex test stands to transform how respiratory diagnostics are conducted in clinical laboratories, ultimately enhancing patient care and laboratory efficiency. As Roche continues to push the boundaries of diagnostic innovation, the healthcare community can look forward to more such advancements that streamline processes and deliver better outcomes for patients worldwide.
Resource: Roche, September 24, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
